Monday, February 6

6:30 p.m.-8:00 p.m. Opening Keynote Presentations
Grand Cypress DEF
Co-Chairpersons: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY; and Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

COP1: Tumor suppressor role revealed
Vishva M. Dixit, Genentech, Inc., South San Francisco, CA

Polycomb-dependent and -independent functions of EZH2 in prostate cancer
Myles Brown, Dana-Farber Cancer Institute, Boston, MA

8:00 p.m.-9:30 p.m. Networking Reception
Upper Pool Deck 1&2

Tuesday, February 7

7:30 a.m.-8:30 a.m. Continental Breakfast
Portico West

8:30 a.m.-10:00 a.m. Session 1: Genomics/Molecular Profiling
Grand Cypress DEF
Chairperson: Elaine Mardis, Washington University School of Medicine, St. Louis, MO

Genomic comparisons of coincident prostate cancer foci
Elaine Mardis

Functional implications of relocation of regulated transcription units in prostate cancer
Michael (Geoff) Rosenfeld, University of California San Diego, La Jolla, CA

Outcome prediction from the pattern of aberrations in prostate cancer genomes
Barry S. Taylor, Memorial Sloan-Kettering Cancer Center, New York, NY

10:00 a.m.-10:20 a.m. Break
Portico West
10:20 a.m.-11:20 a.m. Session 2: Genomics/Molecular Profiling – Prognostic Signatures
   Grand Cypress DEF
   Chairperson: Elaine Mardis, Washington University School of Medicine, St. Louis, MO
   [PLEASE NOTE: This session is not accredited for CME credit.]

   Biological pathways predictive of clinically significant prostate cancer in the context of tumor heterogeneity
   Steven Shak, Genomic Health, Redwood City, CA

   Cell cycle progression genes differentiate indolent from aggressive prostate cancer
   Steve Stone, Myriad Genetics, Salt Lake City, UT

   Development of integrated diagnostic methods for tissue testing
   Gary Pestano, Ventana, a member of the Roche Group, Oro Valley, AZ

11:20 a.m.-12:50 p.m. Session 3: Androgen Receptor Signaling
   Grand Cypress DEF
   Chairperson: Karen Knudsen, Jefferson University Hospital, Philadelphia, PA

   Mechanisms regulating distinct AR transcriptional programs in PCa
   Steven Balk, Beth Israel Deaconess Medical Center, Boston, MA

   Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance
   Karen Knudsen

   Overcoming castration-resistant prostate cancer
   Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

12:50 p.m.-3:20 p.m. Poster Session A/Lunch
   Regency Hall 1-4

3:20 p.m.-4:50 p.m. Session 4: Drug Development
   Grand Cypress DEF
   Chairperson: Johann S. deBono, Institute of Cancer Research, Sutton, United Kingdom

   Immune checkpoint blockade in prostate cancer: New insights and opportunities
   James Allison, Memorial Sloan-Kettering Cancer Center, New York, NY

   Cabozantinib (XL-184) and prostate cancer: Preclinical and clinical profile of a novel agent
   Maha Hussain, University of Michigan Medical School, Ann Arbor, MI

   Conducting hypothesis testing trials for the treatment of advanced prostate cancer
   Johann S. deBono
5:00 p.m.-7:30 p.m. Poster Session B/Reception
   Regency Hall 1-4

7:30 p.m. Evening off/Dinner on own

Wednesday, February 8

7:30 a.m.-8:30 a.m. Continental Breakfast
   Portico West

8:30 a.m.-10:00 a.m. Session 5: ETS Gene Fusions
   Grand Cypress DEF
   Chairperson: Mark A. Rubin, Cornell University Weill Medical College,
   New York, NY

  Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer
  Mark A. Rubin

  Novel therapeutic targets in prostate cancer
  Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

  Context-specific oncogenesis by ETS family transcription factors
  Yu Chen, Memorial Sloan-Kettering Cancer Center, New York, NY

  Title to be announced
  Felix Feng, University of Michigan, Ann Arbor, MI

10:00 a.m.-10:20 a.m. Break

10:20 a.m.-11:50 a.m. Session 6: Prostate Cancer Initiation and Progression
   Grand Cypress DEF
   Chairperson: Michael Shen, Columbia University, New York, NY

  Stem cells and the origin of prostate cancer
  Michael Shen

  Mechanisms and therapeutic targets in metastatic prostate cancer
  Karen Cichowski, Harvard University, Cambridge, MA

  Stem cells and prostate cancer
  Owen N. Witte, University of California, Los Angeles, CA
12:00 p.m.-2:30 p.m. Poster Session C/Lunch
Regency Hall 1-4

2:30 p.m.-5:00 p.m. Session 7: Late-Breaking Research Session
Grand Cypress DEF
Co-Chairpersons: Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY; and Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

Altered AR gene architecture and splicing in castration-resistant prostate cancer
Scott M. Dehm, University of Minnesota Masonic Cancer Center, Minneapolis, MN

Cooperation between androgen receptor and Polycomb in prostate cancer
Jindan Yu, Northwestern University, Chicago, IL

A bad influence: ERG, AR, and prostate cell differentiation
Ray Pagliarini, Novartis, East Hanover, NJ

Transcriptional programs directed by the androgen receptor splicing variants
Jun Luo, Johns Hopkins Medical Institutions, Baltimore, MD

Oncogenic ETS overexpression mimics RAS/MAPK signaling in prostate cells*
Peter C. Hollenhorst, Indiana University, Bloomington, IN

Optimization and applications of a tissue slice culture model of the normal and malignant human prostate*
Sophia L. Maund, Stanford University, Stanford, CA

The snoRNP assembly factor SHQ1 is a novel prostate cancer tumor suppressor gene*
Phillip J. Iaquinta, Memorial Sloan-Kettering Cancer Center, New York, NY

Biochemical recurrence is not a definitive surrogate endpoint for development of clinically useful predictive models for post-prostatectomy patients*
Anamaria Crisan, GenomeDx, Vancouver, BC, Canada

Therapeutic targeting of oncogene-specific tyrosine kinase networks during prostate cancer progression*
Justin M. Drake, University of California, Los Angeles, CA

Cabozantinib (XL184) inhibits androgen-sensitive and castration-resistant prostate cancer in the bone and increases bone formation in nontumored bones*
Eva Corey, University of Washington, Seattle, WA

5:00 p.m. Evening off/Dinner on own

*Short talks from proffered papers
Thursday, February 9

7:30 a.m.-8:30 a.m.  Continental Breakfast
Portico West

8:30 a.m.-10:00 a.m. Session 8: Imaging
Grand Cypress DEF
Chairperson: Martin G. Pomper, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Molecular imaging of androgen receptor signaling in CRPC
Steven M. Larson, Memorial Sloan-Kettering Cancer Center, New York, NY

Diagnosing prostate cancer with image fusion (MRI, PET, CT, US)
Peter Choyke, National Cancer Institute, Bethesda, MD

Molecular imaging agents for prostate cancer: Focus on PSMA
Martin G. Pomper

10:00 a.m.-10:30 a.m. Break
Portico West

10:30 a.m.-12:30 p.m. Session 9: Closing Keynotes and Panel Discussion
Grand Cypress DEF
Co-Chairpersons: Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI; and Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

Inflammation as the trigger of somatic epigenome defects in prostate cancer
William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Role of the microenvironment in prostate cancer progression and resistance
Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX

Panelists:
- Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
- Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX
- William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
- Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY

12:30 p.m.  Departure